Akan M, Skorodumov I, Meinhardt M, Canbeyli R, Unal G. A shea butter-based ketamine ointment: The antidepressant effects of transdermal ketamine in rats. Behav Brain Res. 2023 452:114594. Epub 2023 Jul 23.
Bach P, de Timary P, Gründer G, Cumming P. Molecular Imaging Studies of Alcohol Use Disorder. Curr Top Behav Neurosci. 2023 Jan 14. [Epub ahead of print]
Buchborn T, Kettner HS, Kärtner L, Meinhardt M. The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression. Front Neurosci. 2023 17:1232459.
Gaebler AJ, Fakour N, Stöhr F, Zweerings J, Taebi A, Suslova M, Dukart J, Hipp JF, Adhikari BM, Kochunov P, Muthukumaraswamy SD, Forsyth A, Eggermann T, Kraft F, Kurth I, Paulzen M, Gründer G, Schneider F, Mathiak K. Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI. Transl Psychiatry. 2023 13(1):59.
Hart X, Amann F, Brand J, Eichentopf L, Gründer G. Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study. Pharmacopsychiatry. 2023 56(2):73-80.
Hart X, Heesen S, Schmitz CN, Dörfler S, Wedekind D, Gründer G, Hiemke C, Havemann-Reinecke U. Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder. Eur Arch Psychiatry Clin Neurosci. 2023 273(1):75-83. Epub 2022 Oct 7.
Herwig U, Mertens L, Rosal SP, Koller G, Jungaberle A, Borgwardt S, Gründer G. [Psychedelics in Psychiatry - Development and Current State in Germany]. Fortschr Neurol Psychiatr. 2023 91(7-8):311-318. Epub 2023 Jan 4.
Schmidt C, Wolff M, Gründer G, Jungaberle H. [Attitudes of Mental Health Experts Towards Psilocybin]. Fortschr Neurol Psychiatr. 2023 91(3):80-97. Epub 2022 Jun 20.
Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol. 2023 37(1):107-116.
Urban MM, Stingl MR, Meinhardt M. Mini-review: The neurobiology of treating substance use disorders with classical psychedelics. Front Neurosci. 2023 17:1156319.
Wesner K, Hiemke C, Bergemann N, Egberts KM, Fekete S, Gerlach M, Havemann-Reinecke U, Lense XM, Riemer TG, Schoretsanitis G, Uhr M, Zernig G, Gründer G, Hart XM. Therapeutic Reference Range for Olanzapine in Schizophrenia: Systematic Review on Blood Concentrations, Clinical Effects, and Dopamine Receptor Occupancy. J Clin Psychiatry. 2023 84(5)